LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 39

Search options

  1. Article ; Online: Impact of Alzheimer's association support and engagement in the AD/ADRD research community through the COVID-19 pandemic and beyond.

    Meyers, Emily A / Sexton, Claire / Snyder, Heather M / Carrillo, Maria C

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2023  Volume 19, Issue 7, Page(s) 3222–3225

    Abstract: Introduction: The WHO estimates that 55 million people worldwide have dementia and this number is expected to increase to 139 million by 2050. Founded in 1980, the Alzheimer's Association is the world's leading voluntary health organization in AD/ADRD ... ...

    Abstract Introduction: The WHO estimates that 55 million people worldwide have dementia and this number is expected to increase to 139 million by 2050. Founded in 1980, the Alzheimer's Association is the world's leading voluntary health organization in AD/ADRD care, support and research.
    Methods: Alzheimer's Association-led funding opportunities and awards, conferences and other activities beginning with the COVID-19 pandemic were reviewed.
    Results: The Association remains committed to funding, convening, leading and implementing research studies that accelerate the global effort to eliminate Alzheimer's and all other dementia.
    Discussion: This manuscript describes funding, convening and other global initiatives, influenced in part by the COVID-19 pandemic, to strengthen and drive research forward.
    MeSH term(s) Humans ; Alzheimer Disease/epidemiology ; Alzheimer Disease/therapy ; Dementia/epidemiology ; COVID-19 ; Pandemics
    Language English
    Publishing date 2023-03-05
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.13015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Type I interferon signaling in SARS-CoV-2 associated neurocognitive disorder (SAND): Mapping host-virus interactions to an etiopathogenesis.

    Vavougios, George D / de Erausquin, Gabriel A / Snyder, Heather M

    Frontiers in neurology

    2022  Volume 13, Page(s) 1063298

    Abstract: Epidemiological, clinical, and radiological studies have provided insights into the phenomenology and biological basis of cognitive impairment in COVID-19 survivors. Furthermore, its association with biomarkers associated with neuroinflammation and ... ...

    Abstract Epidemiological, clinical, and radiological studies have provided insights into the phenomenology and biological basis of cognitive impairment in COVID-19 survivors. Furthermore, its association with biomarkers associated with neuroinflammation and neurodegeneration supports the notion that it is a distinct aspect of LongCOVID syndrome with specific underlying biology. Accounting for the latter, translational studies on SARS-CoV-2's interactions with its hosts have provided evidence on type I interferon dysregulation, which is seen in neuroinflammatory and neurodegenerative diseases. To date, studies attempting to describe this overlap have only described common mechanisms. In this manuscript, we attempt to propose a mechanistic model based on the host-virus interaction hypothesis. We discuss the molecular basis for a SARS-CoV-2-associated neurocognitive disorder (SAND) focusing on specific genes and pathways with potential mechanistic implications, several of which have been predicted by Vavougios and their research group. Furthermore, our hypothesis links translational evidence on interferon-responsive gene perturbations introduced by SARS-CoV-2 and known dysregulated pathways in dementia. Discussion emphasizes the crosstalk between central and peripheral immunity
    Language English
    Publishing date 2022-12-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2022.1063298
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Retinal imaging think tank convened by the Alzheimer's Association to examine its promise in the early detection of Alzheimer's.

    Snyder, Peter J / Snyder, Heather M / Bain, Lisa J

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2020  Volume 16, Issue 1, Page(s) 244

    MeSH term(s) Alzheimer Disease/diagnosis ; Congresses as Topic ; Diagnostic Tests, Routine ; Early Diagnosis ; Humans ; Tomography, Optical Coherence
    Language English
    Publishing date 2020-01-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.12034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Data stewardship in FTLD research: Investigator and research participant views.

    Arias, Jalayne J / Tyler, Ana M / Beskow, Laura M / Carillo, Maria C / Dickinson, Susan / Goldman, Jill / Majumder, Mary A / Mello, Michelle M / Snyder, Heather M / Yokoyama, Jennifer S

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2024  Volume 20, Issue 4, Page(s) 2886–2893

    Abstract: Introduction: Federal policies and guidelines have expanded the return of individual results to participants and expectations for data sharing between investigators and through repositories. Here, we report investigators' and study participants' views ... ...

    Abstract Introduction: Federal policies and guidelines have expanded the return of individual results to participants and expectations for data sharing between investigators and through repositories. Here, we report investigators' and study participants' views and experiences with data stewardship practices within frontotemporal lobal degeneration (FTLD) research, which reveal unique ethical challenges.
    Methods: Semi-structured interviews with (1) investigators conducting FTLD research that includes genetic data collection and/or analysis and (2) participants enrolled in a single site longitudinal FTLD study.
    Results: Analysis of the interviews identified three meta themes: perspectives on data sharing, experiences with enrollment and participation, and data management and security as mechanisms for participant protections.
    Discussion: This study identified a set of preliminary gaps and needs regarding data stewardship within FTLD research. The results offer initial insights on ethical challenges to data stewardship aimed at informing future guidelines and policies.
    MeSH term(s) Humans ; Frontotemporal Lobar Degeneration/genetics ; Atrophy ; Research Personnel
    Language English
    Publishing date 2024-03-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.13719
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field.

    Snyder, Heather M / Carrillo, Maria C

    Alzheimer's & dementia (Amsterdam, Netherlands)

    2016  Volume 5, Page(s) 1–2

    Language English
    Publishing date 2016-10-27
    Publishing country United States
    Document type Editorial
    ZDB-ID 2832898-X
    ISSN 2352-8729
    ISSN 2352-8729
    DOI 10.1016/j.dadm.2016.10.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Expanding Representation of Low and Middle Income Countries in Global Dementia Research: Commentary From the Alzheimer's Association.

    Sexton, Claire / Snyder, Heather M / Chandrasekaran, Lakshmi / Worley, Susan / Carrillo, Maria C

    Frontiers in neurology

    2021  Volume 12, Page(s) 633777

    Abstract: Alzheimer's disease (AD) and all other dementia represent a global challenge, with an estimated 50 million individuals in the world living with dementia today. In low and middle income countries (LMICs), the burden of disease often is greater, and some ... ...

    Abstract Alzheimer's disease (AD) and all other dementia represent a global challenge, with an estimated 50 million individuals in the world living with dementia today. In low and middle income countries (LMICs), the burden of disease often is greater, and some of these countries are projected to have some of the largest increases in dementia prevalence during the next few decades. As the world's largest voluntary health organization dedicated to AD and all other dementia, the Alzheimer's Association is committed to its vision of a world without dementia and recognizes the needs, challenges, and opportunities for dementia research in all parts of the world, and especially in LMICs. Currently, the Association is devoting more than $215 million in funding to nearly 600 best-of-field projects in 31 countries, including a significant number of projects that advance and support LMIC-specific research. The innovative work in LMICs is focused on addressing unmet needs or challenges associated with the many unique cultural, demographic, and economic characteristics of these countries. The Association also is expanding leading global forums such as the Alzheimer's Association International Conference (AAIC). In an effort to create new learning and participation opportunities, the Association also has been partnering with other international organizations and collaborating with local leadership to provide AAIC Satellite Symposia (AAIC SS) in LMIC regions around the world. In 2021 and beyond, the Association is committed to continuing these LMIC-focused initiatives, identifying gaps in LMIC research and resources, and enhancing collaboration and communication among researchers in these regions.
    Language English
    Publishing date 2021-03-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2021.633777
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias.

    Shaaban, C Elizabeth / Tudorascu, Dana L / Glymour, M Maria / Cohen, Ann D / Thurston, Rebecca C / Snyder, Heather M / Hohman, Timothy J / Mukherjee, Shubhabrata / Yu, Lan / Snitz, Beth E

    Frontiers in neuroimaging

    2022  Volume 1

    Abstract: Due to needs surrounding rigor and reproducibility, subgroup specific disease knowledge, and questions of external validity, data harmonization is an essential tool in population neuroscience of Alzheimer's disease and related dementias (ADRD). ... ...

    Abstract Due to needs surrounding rigor and reproducibility, subgroup specific disease knowledge, and questions of external validity, data harmonization is an essential tool in population neuroscience of Alzheimer's disease and related dementias (ADRD). Systematic harmonization of data elements is necessary to pool information from heterogeneous samples, and such pooling allows more expansive evaluations of health disparities, more precise effect estimates, and more opportunities to discover effective prevention or treatment strategies. The key goal of this Tutorial in Population Neuroimaging Curriculum, Instruction, and Pedagogy article is to guide researchers in creating a customized population neuroscience of ADRD harmonization training plan to fit their needs or those of their mentees. We provide brief guidance for retrospective data harmonization of multiple data types in this area, including: (1) clinical and demographic, (2) neuropsychological, and (3) neuroimaging data. Core competencies and skills are reviewed, and resources are provided to fill gaps in training as well as data needs. We close with an example study in which harmonization is a critical tool. While several aspects of this tutorial focus specifically on ADRD, the concepts and resources are likely to benefit population neuroscientists working in a range of research areas.
    Language English
    Publishing date 2022-09-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 3123824-5
    ISSN 2813-1193 ; 2813-1193
    ISSN (online) 2813-1193
    ISSN 2813-1193
    DOI 10.3389/fnimg.2022.978350
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective.

    Elahi, Fanny M / Alladi, Suvarna / Black, Sandra E / Claassen, Jurgen A H R / DeCarli, Charles / Hughes, Timothy M / Moonen, Justine / Pajewski, Nicholas M / Price, Brittani R / Satizabal, Claudia / Shaaban, C Elizabeth / Silva, Nárlon C B S / Snyder, Heather M / Sveikata, Lukas / Williamson, Jeff D / Wolters, Frank J / Hainsworth, Atticus H

    Cell reports. Medicine

    2023  Volume 4, Issue 6, Page(s) 101089

    Abstract: A large interventional trial, the Systolic Blood Pressure Intervention Trial sub-study termed Memory and Cognition in Decreased Hypertension (SPRINT-MIND), found reduced risk of cognitive impairment in older adults with intensive, relative to standard, ... ...

    Abstract A large interventional trial, the Systolic Blood Pressure Intervention Trial sub-study termed Memory and Cognition in Decreased Hypertension (SPRINT-MIND), found reduced risk of cognitive impairment in older adults with intensive, relative to standard, blood-pressure-lowering targets (systolic BP < 120 vs. <140 mm Hg). In this perspective, we discuss key questions and make recommendations for clinical practice and for clinical trials, following SPRINT-MIND. Future trials should embody cognitive endpoints appropriate to the participant group, ideally with adaptive designs that ensure robust answers for cognitive and cardiovascular endpoints. Reliable data from diverse populations, including the oldest-old (age > 80 years), will maximize external validity and global implementation of trial findings. New biomarkers will improve phenotyping to stratify patients to optimal treatments. Currently no antihypertensive drug class stands out for dementia risk reduction. Multi-domain interventions, incorporating lifestyle change (exercise, diet) alongside medications, may maximize global impact. Given the low cost and wide availability of antihypertensive drugs, intensive BP reduction may be a cost-effective means to reduce dementia risk in diverse, aging populations worldwide.
    MeSH term(s) Humans ; Aged ; Aged, 80 and over ; Hypertension/drug therapy ; Hypertension/psychology ; Cognitive Dysfunction/drug therapy ; Antihypertensive Agents/therapeutic use ; Dementia/prevention & control ; Internationality
    Chemical Substances Antihypertensive Agents
    Language English
    Publishing date 2023-06-20
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ISSN 2666-3791
    ISSN (online) 2666-3791
    DOI 10.1016/j.xcrm.2023.101089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Letter to the Editor re: Nexus of Cancer & Alzheimer's.

    Carrillo, Maria C / Fillit, Howard / Ganguli, Mary / Knopman, David / Shineman, Diana / Snyder, Heather M

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2017  Volume 13, Issue 6, Page(s) 722

    MeSH term(s) Alzheimer Disease ; Humans ; Neoplasms
    Language English
    Publishing date 2017-04-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1016/j.jalz.2017.03.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Alzheimer's disease: The next frontier-Special Report 2017.

    Karlawish, Jason / Jack, Clifford R / Rocca, Walter A / Snyder, Heather M / Carrillo, Maria C

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2017  Volume 13, Issue 4, Page(s) 374–380

    Abstract: In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific ... ...

    Abstract In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging-Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers-including those detectable in the blood or cerebral spinal fluid, or through neuroimaging-is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.
    MeSH term(s) Alzheimer Disease/diagnosis ; Alzheimer Disease/epidemiology ; Alzheimer Disease/metabolism ; Alzheimer Disease/therapy ; Biomarkers/metabolism ; Humans ; Internationality ; National Institute on Aging (U.S.) ; Practice Guidelines as Topic ; Societies, Medical ; United States
    Chemical Substances Biomarkers
    Language English
    Publishing date 2017-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1016/j.jalz.2017.02.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top